NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today that it has signed a long term supply agreement with Talecris Biotherapeutics, Inc. (“Talecris”) for Cryoprecipitate (“cryo”), a plasma fraction containing coagulation proteins.
